KIORA PHARMACEUTICALS Files S-8 for Employee Stock Plans

TL;DR

**KIORA just cleared the way to give employees more stock, watch for potential dilution.**

AI Summary

KIORA PHARMACEUTICALS INC filed an S-8 on March 25, 2026, to register securities for employee benefit plans. This filing, under File No. 333-294582, allows the company to issue shares to employees, which can dilute existing shareholder value if new shares are created, but also serves as a key tool for attracting and retaining talent. For current or prospective shareholders, this matters because it outlines the framework for how employee compensation might impact the total share count and, consequently, the per-share value of their investment.

Why It Matters

This S-8 filing enables KIORA PHARMACEUTICALS to issue shares to employees, which is crucial for talent retention but could lead to share dilution for existing investors.

Risk Assessment

Risk Level: medium — While common, employee stock plans can dilute existing shareholder value if not managed carefully, posing a moderate risk to per-share earnings.

Analyst Insight

Investors should monitor future filings for the specific number of shares registered under this S-8 and any subsequent share issuances to assess potential dilution.

Key Numbers

• 2026-03-25 — Filing Date (Date the S-8 was filed and became effective)
• 333-294582 — File No. (Unique identifier for this specific S-8 registration)
• 0001372514 — CIK (Central Index Key for KIORA PHARMACEUTICALS INC)

Key Players & Entities

• KIORA PHARMACEUTICALS INC (company) — Filer of the S-8 registration statement
• 0001372514 (company) — CIK of KIORA PHARMACEUTICALS INC
• 333-294582 (dollar_amount) — File number for the S-8 registration
• 2026-03-25 (dollar_amount) — Filing and effectiveness date of the S-8

Forward-Looking Statements

• KIORA PHARMACEUTICALS will likely issue new shares to employees through its benefit plans. (KIORA PHARMACEUTICALS INC) — high confidence, target: 2026-12-31
• The total outstanding share count for KIORA PHARMACEUTICALS may increase due to these employee stock offerings. (KIORA PHARMACEUTICALS INC) — medium confidence, target: 2027-03-25

FAQ

Key Financial Figures

• $0.01 — 0,469 shares of common stock, par value $0.01 per share (the " Common Stock ") issuab

Filing Documents

• kiorapharmaceuticalsinc-sx.htm (S-8) — 82KB
• exfilingfees.htm (EX-FILING FEES) — 29KB
• exhibit51-legalopinionblan.htm (EX-5.1) — 10KB
• exhibit231-auditorconsenth.htm (EX-23.1) — 4KB
• hwlogoa.jpg (GRAPHIC) — 40KB
• imagea.jpg (GRAPHIC) — 16KB
• kiorapharmalogo_rgbxcolor2a.jpg (GRAPHIC) — 341KB
• 0001372514-26-000026.txt ( ) — 786KB
• exfilingfees_htm.xml (XML) — 5KB

Incorporation of Documents by Reference

Item 3. Incorporation of Documents by Reference. The following documents, as filed with the Commission, are incorporated by reference into this Registration Statement by the Registrant (a) the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 25, 2026 and (b) the description of the Registrant's Common Stock in Amendment No. 1 to the Registrant's Registration Statement on Form 8-A (File No. 001-36672) filed with the Commission on July 30, 2015, as amended by Exhibit 4.1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 4, 2020 , including any amendments thereto or reports filed for the purposes of updating this description. All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part of this Registration Statement from the date of the filing of such documents. To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, is or was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

Exhibits

Item 8. Exhibits. The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference. Exhibit Number Description of Exhibit 3.1 Restated Certificate of Incorporation of the Registrant (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on February 20, 2015 and incorporated by reference thereto). 3.2 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed July 10, 2018 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on July 11, 2018 and incorporated by reference thereto). 3.3 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed August 28, 2019 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on August 29, 2019 and incorporated by reference thereto). 3.4 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed June 25, 2020 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on November 8, 2021 and incorporated by reference thereto). 3.5 Certificate of Ownership and Merger of the Registrant, filed November 5, 2021 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on June 26, 2020 and incorporated by reference thereto). 3.6 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed September 26, 2022 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on September 26, 2022 and incorporated by reference thereto). 3 3.7 Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant, filed May 1, 2024 (previously filed as an exhibit to the Registrant's Current Report on Form 8-K filed on May 3, 2024 and incorporated by reference thereto). 3.8 Third Amended and Restate

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Encinitas, State of California, on this 25th day of March, 2026. KIORA PHARMACEUTICALS, INC. By s Brian M. Strem, Ph.D. Brian M. Strem, Ph.D. President and Chief Executive Officer POWER OF ATTORNEY AND SIGNATURES Each of the undersigned officers and directors of the Company hereby constitutes and appoints Brian M. Strem, Ph.D. andor Melissa Tosca as his or her true and lawful attorneys-in-fact and agents, severally, with full power of substitution and resubstitution, in his or her name and on his or her behalf, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power of authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done. Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. 5 Signature Title Date s Brian M. Strem, Ph.D. President, Chief Executive Officer and Director March 25, 2026 Brian M. Strem, Ph.D. (principal executive officer) s Melissa Tosca Chief Financial Officer March 25, 2026 Melissa Tosca (principal financial and accounting officer) s Pra

View Full Filing

View this S-8 filing on SEC EDGAR